Modelling the impact of prison vaccination on hepatitis B transmission within the injecting drug user population of England and Wales

A. J. Sutton; N. J. Gay; William Edmunds

doi:10.1016/j.vaccine.2005.11.055

Modelling the impact of prison vaccination on hepatitis B transmission within the injecting drug user population of England and Wales

A. J. Sutton^*, N. J. Gay, William Edmunds

^*Corresponding author for this work

Public Health England

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

Abstract

A vaccination programme offering hepatitis B (HBV) vaccine at reception into prison has been introduced into selected prisons in England and Wales. The work here considers the impact of prison vaccination on the incidence and prevalence of hepatitis B virus (HBV) in the injecting drug user (IDU) population of England and Wales. A dynamic model of the transmission of HBV in IDUs is developed with key model assumptions and parameters being subject to sensitivity analyses. The base case model (that assumes that the vaccination coverage on prison reception is 5% in 2002, 10% in 2003 and then increases linearly up to 50% of prison receptions being vaccinated by 2006) predicts that the incidence of HBV in IDUs might be reduced by almost 80% in 12 years, and the HBV prevalence (IDUs ever infected by HBV) may be reduced from approximately 18% in 2002 to 7% in 2015. The model presented here demonstrates that HBV vaccination on prison reception can have a significant impact on the prevalence and incidence of HBV in the IDU population over time.

Original language	English
Pages (from-to)	2377-2386
Number of pages	10
Journal	Vaccine
Volume	24
Issue number	13
DOIs	https://doi.org/10.1016/j.vaccine.2005.11.055
Publication status	Published - 20 Mar 2006

Bibliographical note

Funding Information:
Thanks to Matthew Hickman and Emilia Vynnycky for additional helpful comments. This work was supported by Prison Health at the Department of Health and Imperial College London.

Keywords

Hepatitis B vaccination
Injecting drug users
Prison

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2005.11.055

Cite this

@article{72cffb0058264b4f800757b35674fc17,

title = "Modelling the impact of prison vaccination on hepatitis B transmission within the injecting drug user population of England and Wales",

abstract = "A vaccination programme offering hepatitis B (HBV) vaccine at reception into prison has been introduced into selected prisons in England and Wales. The work here considers the impact of prison vaccination on the incidence and prevalence of hepatitis B virus (HBV) in the injecting drug user (IDU) population of England and Wales. A dynamic model of the transmission of HBV in IDUs is developed with key model assumptions and parameters being subject to sensitivity analyses. The base case model (that assumes that the vaccination coverage on prison reception is 5% in 2002, 10% in 2003 and then increases linearly up to 50% of prison receptions being vaccinated by 2006) predicts that the incidence of HBV in IDUs might be reduced by almost 80% in 12 years, and the HBV prevalence (IDUs ever infected by HBV) may be reduced from approximately 18% in 2002 to 7% in 2015. The model presented here demonstrates that HBV vaccination on prison reception can have a significant impact on the prevalence and incidence of HBV in the IDU population over time.",

keywords = "Hepatitis B vaccination, Injecting drug users, Prison",

author = "Sutton, {A. J.} and Gay, {N. J.} and William Edmunds",

note = "Funding Information: Thanks to Matthew Hickman and Emilia Vynnycky for additional helpful comments. This work was supported by Prison Health at the Department of Health and Imperial College London. ",

year = "2006",

month = mar,

day = "20",

doi = "10.1016/j.vaccine.2005.11.055",

language = "English",

volume = "24",

pages = "2377--2386",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "13",

}

TY - JOUR

T1 - Modelling the impact of prison vaccination on hepatitis B transmission within the injecting drug user population of England and Wales

AU - Sutton, A. J.

AU - Gay, N. J.

AU - Edmunds, William

N1 - Funding Information: Thanks to Matthew Hickman and Emilia Vynnycky for additional helpful comments. This work was supported by Prison Health at the Department of Health and Imperial College London.

PY - 2006/3/20

Y1 - 2006/3/20

N2 - A vaccination programme offering hepatitis B (HBV) vaccine at reception into prison has been introduced into selected prisons in England and Wales. The work here considers the impact of prison vaccination on the incidence and prevalence of hepatitis B virus (HBV) in the injecting drug user (IDU) population of England and Wales. A dynamic model of the transmission of HBV in IDUs is developed with key model assumptions and parameters being subject to sensitivity analyses. The base case model (that assumes that the vaccination coverage on prison reception is 5% in 2002, 10% in 2003 and then increases linearly up to 50% of prison receptions being vaccinated by 2006) predicts that the incidence of HBV in IDUs might be reduced by almost 80% in 12 years, and the HBV prevalence (IDUs ever infected by HBV) may be reduced from approximately 18% in 2002 to 7% in 2015. The model presented here demonstrates that HBV vaccination on prison reception can have a significant impact on the prevalence and incidence of HBV in the IDU population over time.

AB - A vaccination programme offering hepatitis B (HBV) vaccine at reception into prison has been introduced into selected prisons in England and Wales. The work here considers the impact of prison vaccination on the incidence and prevalence of hepatitis B virus (HBV) in the injecting drug user (IDU) population of England and Wales. A dynamic model of the transmission of HBV in IDUs is developed with key model assumptions and parameters being subject to sensitivity analyses. The base case model (that assumes that the vaccination coverage on prison reception is 5% in 2002, 10% in 2003 and then increases linearly up to 50% of prison receptions being vaccinated by 2006) predicts that the incidence of HBV in IDUs might be reduced by almost 80% in 12 years, and the HBV prevalence (IDUs ever infected by HBV) may be reduced from approximately 18% in 2002 to 7% in 2015. The model presented here demonstrates that HBV vaccination on prison reception can have a significant impact on the prevalence and incidence of HBV in the IDU population over time.

KW - Hepatitis B vaccination

KW - Injecting drug users

KW - Prison

UR - http://www.scopus.com/inward/record.url?scp=33344459820&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.11.055

DO - 10.1016/j.vaccine.2005.11.055

M3 - Article

C2 - 16384627

AN - SCOPUS:33344459820

VL - 24

SP - 2377

EP - 2386

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 13

ER -

Modelling the impact of prison vaccination on hepatitis B transmission within the injecting drug user population of England and Wales

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this